It might depend on the proportion of the classical types in each trial. But given the phase 2 trial results I would guess maybe an 85% chance of success for the Lucentis trial and 65% chance for the Eyelea one. ASX continuous disclosure obligations should mean each trial is reported when the results come to hand.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-31
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
88.0¢ |
Change
-0.015(1.68%) |
Mkt cap ! $1.083B | |||
| Open | High | Low | Value | Volume |
| 88.5¢ | 88.5¢ | 85.8¢ | $3.209M | 3.692M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 88.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 88.5¢ | 36946 | 3 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |